Immunovant (IMVT) Price & Analysis

Compare

875 Followers

IMVT Stock Chart & Stats

Day’s Range― - ―

52-Week Range$12.72 - $34.47

Previous CloseN/A

Volume171.97K

Average Volume (3M)1.39M

Market Cap

$2.63B

Enterprise Value$2.14B

Total Cash (Recent Filing)$598.91M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta0.87

Next Earnings

Oct 31, 2025

EPS Estimate

-0.71

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.71

Shares Outstanding174,316,830

10 Day Avg. Volume1,481,987

30 Day Avg. Volume1,394,583

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.81

Enterprise Value/Revenue13.34K

Enterprise Value/Gross Profit-9.93K

Enterprise Value/Ebitda-4.87

Forecast

1Y Price Target

$40.83

Price Target Upside153.29% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering13

Bulls Say, Bears Say

Bulls Say

Clinical TrialsIMVT has initiated two parallel Ph3 trials with a design consistency with Ph2, which is seen as promising for the probability of success.

Disease Modification PotentialOff-treatment results exceeded expectations and suggest that FcRn inhibition has the potential to have a disease-modifying effect in Graves' Disease.

Treatment EfficacyBatoclimab achieved a compelling 76% response rate on the primary endpoint of T3/T4 normalization without an increase of anti-thyroid drugs, showcasing its effectiveness in treating Graves’ disease.

Bears Say

Investor SentimentThe company has a short interest of 22.8% of the float, which might indicate some investor skepticism.

Trial Recruitment ChallengesThere remain several questions on how much the J&J study missed by, the performance of the control arm, and the correlation between response and depth of IgG reduction.

Immunovant News

3 Best Stocks to Buy Now, 9/4/2025, According to Top Analysts

Which stocks are best to buy now? According to Top Wall Street Analysts, the three stocks listed below...

1d ago

IVA

IMVT

Immunovant: 80% of patients demonstrate response in Graves’ disease trial

Immunovant (IMVT) shared an abstract with six-month off-treatment data in uncontrolled Graves’ disease patients treated with batoclimab for...

2d ago

IMVT

Immunovant price target lowered to $30 from $33 at BofA

BofA analyst Jason Gerberry lowered the firm’s price target on Immunovant (IMVT) to $30 from $33 and keeps...

25d ago

IMVT

Immunovant price target lowered to $37 from $40 at JPMorgan

JPMorgan lowered the firm’s price target on Immunovant (IMVT) to $37 from $40 and keeps an Overweight rating...

25d ago

IMVT

Immunovant price target lowered to $57 from $58 at Citi

Citi analyst Samantha Semenkow lowered the firm’s price target on Immunovant (IMVT) to $57 from $58 and keeps...

25d ago

IMVT

Immunovant reports Q EPS (71c), consensus (67c)

“We remain laser-focused on executing on our development plans, and all ongoing trials remain on track as we...

26d ago

IMVT

Immunovant’s Batoclimab Shows Promising Results in Phase 2 Study for Graves’ Disease, Earning Buy Rating

H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating on Immunovant today and set a price target of...

2d ago

IMVT

Immunovant’s Promising Clinical Data and Strategic Advancements Drive Buy Rating

Analyst Sam Slutsky from LifeSci Capital maintained a Buy rating on Immunovant and keeping the price target at...

2d ago

IMVT

Immunovant Announces Promising Graves’ Disease Study Results

Immunovant ( ($IMVT) ) just unveiled an announcement. On September 3, 2025, Immunovant announced promising six-month off-treatment data...

2d ago

IMVT

Optimistic Buy Rating for Immunovant: Strategic Positioning and Promising Monotherapy Potential

Analyst Sam Slutsky from LifeSci Capital maintained a Buy rating on Immunovant and keeping the price target at...

8d ago

IMVT

Immunovant Stockholders Approve Key Governance Decisions

Immunovant ( ($IMVT) ) just unveiled an update. On August 27, 2025, Immunovant, Inc. held its Annual Meeting...

8d ago

IMVT

Immunovant’s Promising Pipeline and Strategic Focus Justify Buy Rating

Immunovant, the Healthcare sector company, was revisited by a Wall Street analyst on August 11. Analyst Thomas Smith...

22d ago

IMVT

Immunovant’s Promising Pipeline and Strong Financial Position Signal a Buy Rating

Wells Fargo analyst Derek Archila maintained a Buy rating on Immunovant yesterday and set a price target of...

25d ago

IMVT

Immunovant’s Promising Advances in Graves’ Disease Treatment Drive Buy Rating

Douglas Tsao, an analyst from H.C. Wainwright, reiterated the Buy rating on Immunovant. The associated price target remains...

25d ago

IMVT

IMVT FAQ

What was Immunovant’s price range in the past 12 months?

Immunovant lowest stock price was $12.72 and its highest was $34.47 in the past 12 months.

What is Immunovant’s market cap?

Immunovant’s market cap is $2.63B.

When is Immunovant’s upcoming earnings report date?

Immunovant’s upcoming earnings report date is Oct 31, 2025 which is in 55 days.

How were Immunovant’s earnings last quarter?

Immunovant released its earnings results on Aug 11, 2025. The company reported -$0.71 earnings per share for the quarter, missing the consensus estimate of -$0.68 by -$0.03.

Is Immunovant overvalued?

According to Wall Street analysts Immunovant’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Immunovant pay dividends?

Immunovant does not currently pay dividends.

What is Immunovant’s EPS estimate?

Immunovant’s EPS estimate is -0.71.

How many shares outstanding does Immunovant have?

Immunovant has 174,316,830 shares outstanding.

What happened to Immunovant’s price movement after its last earnings report?

Immunovant reported an EPS of -$0.71 in its last earnings report, missing expectations of -$0.68. Following the earnings report the stock price went down -4.528%.

Which hedge fund is a major shareholder of Immunovant?

Currently, no hedge funds are holding shares in IMVT

Immunovant Stock Smart Score

Underperform

Fundamentals

Return on Equity

-77.58%

Trailing 12-Months

Asset Growth

12.17%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Immunovant

Immunovant, Inc. (IMVT) is a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with autoimmune diseases. The company is dedicated to creating transformative treatments by utilizing its expertise in immunology. Its lead product candidate, batoclimab, is a monoclonal antibody targeting the neonatal Fc receptor (FcRn), which is being developed for the treatment of various autoimmune disorders.

Immunovant (IMVT) Earnings & Revenues

Historic Earnings Reports

IMVT Stock 12 Month Forecast

Average Price Target

$40.83

▲(153.29% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"14":"$14","25":"$25","36":"$36","47":"$47","58":"$58"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":57,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$57.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":40.83,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$40.83</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":18,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$18.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[14,25,36,47,58],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.07,18.295384615384616,21.520769230769233,24.746153846153845,27.97153846153846,31.196923076923078,34.42230769230769,37.64769230769231,40.87307692307692,44.098461538461535,47.323846153846155,50.54923076923077,53.77461538461538,{"y":57,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.07,17.051538461538463,19.033076923076923,21.014615384615386,22.996153846153845,24.97769230769231,26.95923076923077,28.94076923076923,30.92230769230769,32.90384615384615,34.885384615384616,36.86692307692307,38.848461538461535,{"y":40.83,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.07,15.295384615384616,15.52076923076923,15.746153846153847,15.971538461538461,16.196923076923078,16.422307692307694,16.647692307692306,16.873076923076923,17.09846153846154,17.323846153846155,17.549230769230768,17.774615384615384,{"y":18,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":30.9,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.45,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.39,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.79,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.77,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.74,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.6,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.2,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.9,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.41,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.15,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.71,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.07,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >